Enzalutamide Soft Capsules 恩杂鲁胺软胶囊

Enzalutamide soft capsule is an androgen receptor inhibitor, mainly used to treat prostate cancer.
Patients with a history of allergy to the ingredients and excipients of this product are prohibited from taking it; it is not suitable for women, and is contraindicated for women who are pregnant or planning to become pregnant.
Male patients should use condoms and other contraceptive methods to strictly avoid… Details
Enzalutamide soft capsule comprehensive interpretation

Effects:
This product is suitable for the treatment of adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or have mild symptoms after androgen deprivation therapy (ADT) failure and have not received chemotherapy.
Usage and Dosage:
The drug should be taken under the guidance of a specialist with experience in prostate cancer treatment. Recommended dose: 160 mg of enzalutamide (4 40 mg soft capsules), once a day, orally. Method of administration: This product is for oral use. Do not chew, dissolve or open the soft capsule. The whole capsule should be taken with water, with or without meals. Non-surgical castration patients should continue to use luteinizing hormone-releasing hormone (LHRH) analogs for medical castration during treatment. If the patient fails to take the medicine on time, the prescribed dose should be taken as soon as possible. If a full day of medication is missed, the medication should be continued at the usual daily dose the next day. If the patient experiences ≥ grade 3 toxicity or intolerable adverse reactions, the drug should be discontinued for 1 week or until the symptoms subside to ≤ grade 2, and then the drug should be restarted at the same dose or a reduced dose (120 or 80 mg) if necessary. Co-administration with strong CYP2C8 inhibitors: Co-administration with strong CYP2C8 inhibitors should be avoided as much as possible. If the patient must co-use a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily. After stopping co-administration of a strong CYP2C8 inhibitor, the dose of enzalutamide should be restored to the dose level before co-administration. Hepatic impairment: No dose adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh A, B or C, respectively). Renal impairment: No dosage adjustment is required for patients with mild or moderate renal impairment. Patients with severe renal impairment or end-stage renal disease should use this product with caution.
Drug contraindications:
Allergic to this product is prohibited. It is prohibited during pregnancy. Use with caution during lactation.
Related dosage forms:
Capsules